In view that trametinib treatment downregulates Id1 expression, we analyzed the effects of this treatment on Id1 expression and tumor growth in CMT167 and LLC KRAS-mutant LUAD syngeneic tumors. The gene discussed is KRAS; the disease is neoplasm.